<?xml version="1.0" encoding="UTF-8"?>

<ResearchStudy xmlns="http://hl7.org/fhir">
  <id value="2022-500014-26-00-example-v2"/>
  <meta>
    <lastUpdated value="2023-04-12T00:00:00.000Z"/>
    <profile value="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"/>
  </meta>
  <text>
    <status value="extensions"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: ResearchStudy 2022-500014-26-00-example-v2</b></p><a name="2022-500014-26-00-example-v2"> </a><a name="hc2022-500014-26-00-example-v2"> </a><a name="2022-500014-26-00-example-v2-fr-FR"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Last updated: 2023-04-12 00:00:00+0000</p><p style="margin-bottom: 0px">Profil: <a href="StructureDefinition-eclaire-researchstudy.html">ECLAIREResearchStudy</a></p></div><p><b>ECLAIREReviewDate</b>: 2023-04-12 00:00:00+0000</p><p><b>ECLAIRETherapeuticArea</b>: [Traduction locale] Diseases [C] - Neoplasms [C04]</p><p><b>ECLAIRERecruitmentPeriod</b>: 2022-06-30 00:00:00+0000 --&gt; (ongoing)</p><blockquote><p><b>ECLAIREassociatedPartyR5</b></p><ul><li>name: F. Hoffmann-La Roche AG</li><li>role: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system lead-sponsor}">lead-sponsor</span></li><li>party: <a href="Organization/2022-500014-26-00-primary-sponsor">Reference to primary sponsor</a></li></ul></blockquote><p><b>identifier</b>: 2022-500014-26-00 (use: official, )</p><p><b>title</b>: [Traduction locale] A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER</p><p><b>status</b>: Active</p><p><b>phase</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/research-study-phase phase-3}">Therapeutic confirmatory  (Phase III)</span></p><p><b>category</b>: <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system REG536}">REG536 (CTIS)</span>, <span title="Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system study-ctis}">un essai clinique (CTIS)</span></p><p><b>condition</b>: <span title="Codes:">[Traduction locale] Locally-Advanced or Metastatic breast cancer (MBC)</span>, <span title="Codes:{https://www.meddra.org 10070575}">Cancer du sein à récepteurs aux oestrogènes positifs</span>, <span title="Codes:{https://www.meddra.org 10065430}">Cancer du sein HER2 positif</span></p><p><b>contact</b>: ph: 0041616881111(Work),<a href="mailto:global.rochegenentechtrials@roche.com">global.rochegenentechtrials@roche.com</a>, ph: -unknown-(Work),<a href="mailto:null"/></p><p><b>location</b>: <span title="Codes:{urn:iso:std:iso:3166 BE}">Belgium</span>, <span title="Codes:{urn:iso:std:iso:3166 DE}">Germany</span>, <span title="Codes:{urn:iso:std:iso:3166 ES}">Spain</span>, <span title="Codes:{urn:iso:std:iso:3166 FR}">France</span>, <span title="Codes:{urn:iso:std:iso:3166 HU}">Hungary</span>, <span title="Codes:{urn:iso:std:iso:3166 IT}">Italy</span>, <span title="Codes:{urn:iso:std:iso:3166 PL}">Poland</span>, <span title="Codes:{urn:iso:std:iso:3166 PT}">Portugal</span></p><p><b>enrollment</b>: <a href="Group/2022-500014-26-00-enrollment-group">Reference to group detailing study characteristics</a></p><p><b>site</b>: <a href="Location/2022-500014-26-00-0-site">Reference to site</a></p></div>
  </text>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date">
    <valueInstant value="2023-04-12T00:00:00.000Z"/>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area">
    <valueString value="[Traduction locale] Diseases [C] - Neoplasms [C04]"/>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period">
    <valuePeriod>
      <start value="2022-06-30T00:00:00.000Z"/>
    </valuePeriod>
  </extension>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.associatedParty">
    <extension url="name">
      <valueString value="F. Hoffmann-La Roche AG"/>
    </extension>
    <extension url="role">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system"/>
          <version value="0.3.0"/>
          <code value="lead-sponsor"/>
          <display value="lead-sponsor"/>
        </coding>
      </valueCodeableConcept>
    </extension>
    <extension url="party">
      <valueReference>
        <reference value="Organization/2022-500014-26-00-primary-sponsor"/>
        <type value="Organization"/>
        <display value="Reference to primary sponsor"/>
      </valueReference>
    </extension>
  </extension>
  <identifier>
    <use value="official"/>
    <value value="2022-500014-26-00"/>
    <assigner>
      <reference value="Organization/ctis"/>
      <type value="Organization"/>
      <display value="Reference to primary assigner"/>
    </assigner>
  </identifier>
  <title value="[Traduction locale] A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER"/>
  <status value="active"/>
  <phase>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
      <code value="phase-3"/>
      <display value="Therapeutic confirmatory  (Phase III)"/>
    </coding>
  </phase>
  <category>
    <coding>
      <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system"/>
      <version value="0.3.0"/>
      <code value="REG536"/>
      <display value="REG536 (CTIS)"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system"/>
      <version value="0.3.0"/>
      <code value="study-ctis"/>
      <display value="un essai clinique (CTIS)"/>
    </coding>
  </category>
  <condition id="disease-condition-2022-500014-26-00">
    <text value="[Traduction locale] Locally-Advanced or Metastatic breast cancer (MBC)"/>
  </condition>
  <condition id="meddra-condition-2022-500014-26-00-10070575">
    <coding>
      <system value="https://www.meddra.org"/>
      <version value="3.0.0"/>
      <code value="10070575"/>
      <display value="Cancer du sein à récepteurs aux oestrogènes positifs"/>
    </coding>
  </condition>
  <condition id="meddra-condition-2022-500014-26-00-10065430">
    <coding>
      <system value="https://www.meddra.org"/>
      <version value="3.0.0"/>
      <code value="10065430"/>
      <display value="Cancer du sein HER2 positif"/>
    </coding>
  </condition>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
        <family value="Trial Information Support Line-TISL, Switzerland"/>
        <given value="Head of EU"/>
      </valueHumanName>
    </extension>
    <telecom>
      <system value="phone"/>
      <value value="0041616881111"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="global.rochegenentechtrials@roche.com"/>
      <use value="work"/>
    </telecom>
  </contact>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system"/>
          <version value="0.3.0"/>
          <code value="PUB"/>
          <display value="Publique / Public"/>
        </coding>
      </valueCodeableConcept>
    </extension>
    <telecom>
      <system value="phone"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <use value="work"/>
    </telecom>
  </contact>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="BE"/>
      <display value="Belgium"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="DE"/>
      <display value="Germany"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="ES"/>
      <display value="Spain"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="FR"/>
      <display value="France"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="HU"/>
      <display value="Hungary"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="IT"/>
      <display value="Italy"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="PL"/>
      <display value="Poland"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="PT"/>
      <display value="Portugal"/>
    </coding>
  </location>
  <enrollment>
    <reference value="Group/2022-500014-26-00-enrollment-group"/>
    <type value="Group"/>
    <display value="Reference to group detailing study characteristics"/>
  </enrollment>
  <site>
    <reference value="Location/2022-500014-26-00-0-site"/>
    <type value="Location"/>
    <display value="Reference to site"/>
  </site>
</ResearchStudy>